Windtree Therapeutics, Inc. (NASDAQ:WINT) Short Interest Update

Windtree Therapeutics, Inc. (NASDAQ:WINT) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 47,100 shares, a growth of 20.8% from the May 31st total of 39,000 shares. Currently, 10.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 28,400 shares, the short-interest ratio is currently 1.7 days.

Windtree Therapeutics Stock Down 0.3 %

Windtree Therapeutics stock opened at $3.20 on Tuesday. Windtree Therapeutics has a twelve month low of $2.89 and a twelve month high of $30.06. The company’s 50-day moving average price is $3.91 and its 200-day moving average price is $6.71. The company has a market cap of $1.89 million, a PE ratio of -0.09 and a beta of 0.56.

Windtree Therapeutics (NASDAQ:WINT) last issued its quarterly earnings data on Tuesday, April 16th. The company reported ($13.31) earnings per share (EPS) for the quarter. As a group, sell-side analysts expect that Windtree Therapeutics will post -24.93 earnings per share for the current fiscal year.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.